NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

MRKR

Marker Therapeutics Inc

Jun 23 • 10:45AM ET

1.47

Dollar change +0.02
Percentage change 1.38	%

Healthcare • Biotechnology • USA • NASD

Peers: NVAX IOVA ALLO ADAP KPTI TVRD MGNX AGEN CERS TXMD

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.33	Insider Own	30.21%	Shs Outstand	11.21M	Perf Week	-8.13%
Market Cap	16.64M	Forward P/E	-	EPS next Y	-1.78	Insider Trans	19.81%	Shs Float	7.90M	Perf Month	33.64%
Enterprise Value	2.95M	PEG	-	EPS next Q	-0.29	Inst Own	17.29%	Short Float	1.50%	Perf Quarter	17.60%
Income	-12.78M	P/S	2.92	EPS this Y	-62.75%	Inst Trans	-13.58%	Short Ratio	1.12	Perf Half Y	-69.75%
Sales	5.70M	P/B	1.14	EPS next Y	8.09%	ROA	-82.26%	Short Interest	0.12M	Perf YTD	-52.73%
Book/sh	1.29	P/C	1.22	EPS next 5Y	7.40%	ROE	-97.30%	52W High	5.99 -75.46%	Perf Year	-68.18%
Cash/sh	1.21	P/FCF	-	EPS past 3/5Y	39.79% 23.96%	ROIC	-88.22%	52W Low	0.95 54.74%	Perf 3Y	-45.56%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	74.44% 98.63%	Gross Margin	-	Volatility	1.81% 8.58%	Perf 5Y	-93.29%
Dividend TTM	-	EV/Sales	0.52	EPS Y/Y TTM	18.52%	Oper. Margin	-223.40%	ATR (14)	0.15	Perf 10Y	-98.64%
Dividend Ex-Date	-	Quick Ratio	6.79	Sales Y/Y TTM	71.53%	Profit Margin	-224.45%	RSI (14)	51.32	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.79	EPS Q/Q	-48.92%	SMA20	-1.57%	Beta	1.45	Target Price	8.17
Payout	-	Debt/Eq	0.00	Sales Q/Q	-71.94%	SMA50	13.62%	Rel Volume	0.31	Prev Close	1.45
Employees	5	LT Debt/Eq	0.00	Earnings	May 16 BMO	SMA200	-36.45%	Avg Volume	106.24K	Price	1.47
IPO	Jan 05, 1998	Option/Short	No / Yes	EPS/Sales Surpr.	24.56% 99.94%	Trades		Volume	7,555	Change	1.38%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-05-25	Initiated	Canaccord Genuity	Buy	$8
Mar-25-21	Initiated	Piper Sandler	Overweight	$6
Mar-19-21	Initiated	Cantor Fitzgerald	Overweight	$6
May-12-20	Downgrade	Piper Sandler	Overweight → Neutral	$5 → $2.50
May-30-19	Initiated	ROTH Capital	Buy
Mar-01-19	Initiated	Janney	Buy
Dec-03-18	Upgrade	Piper Jaffray	Neutral → Overweight

Jun-17-25 08:00AM	Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma (GlobeNewswire)
May-20-25 08:00AM	Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma (GlobeNewswire)
May-19-25 08:00AM	Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies (GlobeNewswire)
Apr-01-25 08:00AM	Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference (GlobeNewswire) -7.32%
Mar-31-25 08:45AM	Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results (GlobeNewswire)
07:00AM	Loading…
Feb-25-25 07:00AM	Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference (GlobeNewswire)
Dec-19-24 08:06AM	Marker Therapeutics Announces $16.1 Million Private Placement (GlobeNewswire) -7.44%
08:05AM	Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma (GlobeNewswire)
Dec-17-24 07:00AM	Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer (GlobeNewswire) +17.68%
Dec-10-24 08:30AM	Marker Therapeutics to Present at the 2024 Ladenburg Thalmann and Co. Virtual Oncology Innovators and Investors Symposium (GlobeNewswire)
08:30AM	Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium (GlobeNewswire)
Nov-26-24 11:00AM	Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit (GlobeNewswire)
Nov-14-24 04:30PM	Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -12.29%
Oct-22-24 08:20AM	Marker Therapeutics price target raised to $19 from $11 at Ladenburg (TipRanks) +22.70%
Sep-26-24 02:33PM	AML cell therapy trials to watch in 2024 targeting GvHD (Clinical Trials Arena) +6.59%
08:00AM	Loading…
Aug-28-24 08:00AM	Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors (GlobeNewswire)
Aug-14-24 04:30PM	Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -5.41%
Aug-12-24 07:00AM	Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma (GlobeNewswire)
Jun-28-24 11:52AM	MRKR Stock Earnings: Marker Therapeutics Reported Results for Q4 2023 (InvestorPlace) +12.42%
May-15-24 11:53PM	MRKR Stock Earnings: Marker Therapeutics Reported Results for Q1 2024 (InvestorPlace)
04:15PM	Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-08-24 07:00AM	Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies (GlobeNewswire)
Mar-25-24 05:45PM	Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results (GlobeNewswire) -10.74%
Mar-22-24 12:30PM	Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (GlobeNewswire) +5.82%
Jan-22-24 07:30AM	Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for Neldaleucel as Nonproprietary Name for MT-601 (GlobeNewswire) +5.56%
Jan-08-24 09:31AM	Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization (Benzinga)
08:24AM	Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization (GlobeNewswire)
Dec-21-23 11:00AM	Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During J.P. Morgan Week 2024 (GlobeNewswire)
Dec-11-23 07:00AM	Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse (GlobeNewswire) +46.85%
Nov-09-23 05:00PM	Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -8.56%
07:00AM	Loading…
Sep-11-23 07:00AM	Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse (GlobeNewswire) +11.41%
Aug-30-23 08:00AM	Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +6.75%
Aug-25-23 12:07PM	Marker Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance (GuruFocus.com) -5.52%
Aug-17-23 09:03AM	Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies (Newsfile)
Aug-14-23 04:30PM	Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +25.75%
Aug-07-23 07:00AM	Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program (GlobeNewswire)
Jul-26-23 07:00AM	Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023 (GlobeNewswire)
Jul-22-23 08:12AM	Marker Therapeutics (NASDAQ:MRKR) hikes 26% this week, taking one-year gains to 95% (Simply Wall St.)
Jul-10-23 07:00AM	European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients (GlobeNewswire) +23.04%
Jun-26-23 07:00AM	Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration (GlobeNewswire) -6.59%
Jun-12-23 07:00AM	Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial (GlobeNewswire) +19.52%
May-31-23 06:30AM	Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells (GlobeNewswire) +33.84%
May-17-23 06:11AM	Marker Therapeutics First Quarter 2023 Earnings: US$0.57 loss per share (vs US$1.19 loss in 1Q 2022) (Simply Wall St.)
May-08-23 07:30AM	Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer (GlobeNewswire) +15.97%
May-01-23 07:30AM	Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady (GlobeNewswire) +16.47%
Mar-22-23 08:10AM	Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results (GlobeNewswire) -31.82%
Dec-13-22 07:23PM	Marker Therapeutics inks $25M stock purchase agreement with Lincoln Park Capital Fund (American City Business Journals)
07:00AM	Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million (GlobeNewswire)
Nov-22-22 07:28AM	Here's Why Marker Therapeutics (NASDAQ:MRKR) Must Use Its Cash Wisely (Simply Wall St.)
07:00AM	Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer (GlobeNewswire)
Nov-10-22 05:35PM	MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Marker Therapeutics Reports Q3 2022 Operating and Financial Results (GlobeNewswire)
Sep-13-22 07:00AM	Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Markers Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML (GlobeNewswire) +7.12%
Sep-08-22 07:00AM	Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference (GlobeNewswire) +31.50%
Aug-11-22 04:22PM	Marker Therapeutics Reports Q2 2022 Operating and Financial Results (GlobeNewswire) -8.08% -12.24%
Aug-04-22 04:37PM	Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma (GlobeNewswire) +63.64%
Jun-15-22 07:06AM	Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky (Simply Wall St.)
May-13-22 07:00AM	Marker Therapeutics Reports Q1 2022 Operating and Financial Results (GlobeNewswire)
May-04-22 10:30AM	Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting (GlobeNewswire) +8.00%
Apr-26-22 07:00AM	Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf (GlobeNewswire)
Mar-17-22 05:45PM	Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results (GlobeNewswire)
Mar-07-22 04:05PM	Marker Therapeutics to Present at Two Upcoming March Investor Conferences (GlobeNewswire) +8.86%
Feb-17-22 01:08PM	Why Are Marker Therapeutics Shares Trading Lower On Thursday? (Benzinga) -25.99%
Feb-16-22 04:30PM	Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion (GlobeNewswire)
Feb-08-22 04:05PM	Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022 (GlobeNewswire)
Jan-20-22 06:38AM	Marker Therapeutics Stock Gains On FDA Orphan Drug Tag For Second MultiTAA-Cell Therapy For Pancreatic Cancer (Benzinga) -10.67%
Jan-19-22 04:49PM	Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer (GlobeNewswire)
Jan-06-22 08:53AM	Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Invest In Growth? (Simply Wall St.) -5.51%
Dec-31-21 09:40AM	Are Options Traders Betting on a Big Move in Marker Therapeutics (MRKR) Stock? (Zacks)
Dec-09-21 07:00AM	Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors (PR Newswire)
Nov-18-21 04:05PM	Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting (PR Newswire) -7.35%
Nov-10-21 04:05PM	Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results (PR Newswire)
Oct-08-21 09:24AM	Bullish insiders bet US$1.3m on Marker Therapeutics, Inc. (NASDAQ:MRKR) (Simply Wall St.)
Sep-07-21 04:05PM	Marker Therapeutics to Present at Three Upcoming September Investor Conferences (PR Newswire)
Aug-20-21 12:00PM	38 Stocks Moving In Friday's Mid-Day Session (Benzinga) +8.33%
Aug-19-21 04:05PM	Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas (PR Newswire) -5.08%
Aug-10-21 04:01PM	Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results (PR Newswire)
Aug-09-21 06:57AM	Is Marker Therapeutics, Inc.'s (NASDAQ:MRKR) Shareholder Ownership Skewed Towards Insiders? (Simply Wall St.)
Jul-28-21 04:05PM	Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility (PR Newswire)
Jul-06-21 07:00AM	Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML (PR Newswire)
Jun-29-21 09:01AM	Marker Therapeutics, Inc. (MRKR): Are Hedge Funds Right About This Stock? (Insider Monkey)
Jun-16-21 04:05PM	Marker Therapeutics to Present at the Virtual Raymond James Human Health Innovation Conference (PR Newswire)
May-20-21 04:06AM	Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation (Simply Wall St.) +5.44%
May-12-21 04:05PM	Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results (PR Newswire) -8.47%
02:45PM	Marker Therapeutics, Inc. to Host Earnings Call (ACCESSWIRE)
Apr-29-21 04:05PM	Marker Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast on Wednesday, May 12, 2021 (PR Newswire)
Apr-27-21 07:41PM	Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at the 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting (PR Newswire) +8.91%
Apr-08-21 03:23PM	Study shows wearables could detect COVID-19 earlier (Yahoo Finance Video) +6.31%
Apr-07-21 08:32AM	Do Options Traders Know Something About Marker Therapeutics (MRKR) Stock We Don't? (Zacks) -8.85%
Mar-16-21 04:57PM	Marker Therapeutics, Inc. Announces Closing of Public Offering of Common Stock (PR Newswire)
Mar-15-21 07:00AM	Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference (PR Newswire)
Mar-12-21 08:00AM	Marker Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock (PR Newswire) -23.32%
Mar-11-21 04:10PM	Marker Therapeutics, Inc. Announces Proposed Public Offering of Common Stock (PR Newswire)
Mar-09-21 04:12PM	Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results (PR Newswire) +6.81%
Mar-03-21 07:00AM	Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplant (PR Newswire)
Mar-01-21 05:03AM	What Type Of Shareholders Make Up Marker Therapeutics, Inc.'s (NASDAQ:MRKR) Share Registry? (Simply Wall St.) +5.79%
Jan-13-21 07:00AM	Marker Therapeutics Announces Completion of New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates (PR Newswire) +8.33%
Jan-05-21 07:00AM	Marker Therapeutics Announces FDA Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial (PR Newswire) +17.69%
Nov-30-20 02:30AM	Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Invest In Growth? (Simply Wall St.)
Nov-09-20 04:01PM	Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results (PR Newswire)

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ELMS STEVE	Director	Dec 23 '24	Buy	3.20	11,085	35,472	325,370	Dec 26 04:01 PM
New Enterprise Associates 16,	10% Owner	Dec 23 '24	Buy	3.20	554,250	1,773,600	1,625,678	Dec 23 04:40 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRKR

Marker Therapeutics Inc

Upgrade your FINVIZ experience